← Leaderboards
David Bruyette
Anivive Lifesciences, Inc
$5,639,710
Attributed
$5,639,710
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.9M · FY2020–24$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,889,710 · 1
FDA$750,000 · 2
By mechanism
N01$4,889,710 · 1
R01$750,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Advanced Development”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Joel A Lipkin · Four Points Technology, Llc$181,896,915
- Kimberly Smith · Ppd Development Lp$115,671,664
Research focus
Advanced DevelopmentAnimal ModelBiodefenseCoccidioides PosadasiiCommunicable DiseasesContractsDisease OutbreaksEfficacy EvaluationEfficacy TestingEmerging Communicable DiseasesFormulationImmunogenicityManufactureResponseSafetyStability TestingToxicologyVaccine CandidateVaccine DevelopmentVaccines
Grant awards (4)
Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases$4,889,710
N01 · FY2024 · AI · contact PI
Comparability protocol for 22.5 mg tablets (NADA # 141-526)$250,000
R01 · FY2023 · FD · contact PI
A multi-center pivotal field study to confirm the effectiveness and safety of verdinexor for the treatment of lymphoma in dogs.$250,000
R01 · FY2021 · FD · contact PI
A multi-center pivotal field study to confirm the effectiveness and safety of verdinexor for the treatment of lymphoma in dogs.$250,000
R01 · FY2020 · FD · contact PI